We are moving from what I call the 'old Pfizer,' a company characterized by the medicines we launched so successfully in the 1990s, to the 'next generation' Pfizer, characterized by a new wave of important medicines now reaching patients.
We are moving from what I call the 'old Pfizer,' a company characterized by the medicines we launched so successfully in the 1990s, to the 'next generation' Pfizer, characterized by a new wave of important medicines now reaching patients.
We share some of your disappointment in some of the news reported today, ... Beyond the quarterly numbers, we ask you to look at the greater picture of a Pfizer in transition.
The media needs to inform the public without terrorizing the public. We're prepared to defend our products in the public domain.
This is an important victory not only for Pfizer but for all innovators pursuing high-risk medical discoveries.
© 2020 Inspirational Stories
© 2020 Inspirational Stories